Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. - Wikidata - awgldk - TriplyDB

Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

http://www.wikidata.org/entity/Q37082518

about

Advances in sarcoma diagnostics and treatment Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.Soft tissue sarcomas: From a morphological to a molecular biological approach.[Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.

P2860

Q28069695-6E3339B7-733A-4150-8F72-B36B928BD0C8 Q38699774-6DDE4492-17D2-4C02-9B39-4C39031D16F1 Q47244891-4E93943C-6874-4174-9B70-A462B351CC61 Q49335269-C8319E8C-FFFA-4F1D-80E3-32F48548B81B Q51817033-F9A29308-0E09-496F-B864-52ECC9E5E1BA Q53209590-5633F9B3-0865-44B9-837C-7963276DA826 Q54489272-20513BA1-6B06-440A-8DF7-AE8B627EDF91

P2860

Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

http://www.wikidata.org/entity/Q37082518

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 March 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@en

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@nl

type

label

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@en

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@nl

prefLabel

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@en

Cancer-testis antigens PRAME a ...... ognosis in myxoid liposarcoma.

@nl

P1433

Q37082518-DA050C69-2F93-4944-A0FC-4291D0F899A6

P1476

Q37082518-7086BDCB-46AA-40C2-AB3F-646FB7671D77

P2093

Q37082518-5D46B4DC-6C46-4E50-B792-55E883448156

Q37082518-61FF9ECF-8C07-4818-98F1-D6823AE29A04

Q37082518-76371874-7004-4A0C-A3DE-F6A9E5B679B6

Q37082518-93A4939A-5CBF-4CA1-B974-A1283D85B1D4

Q37082518-95BC451D-D1F3-411B-8DCB-4D92E8D7A94C

Q37082518-C9F13A4B-B860-4D0C-8A59-6A84E5D4CB82

Q37082518-D5C3BF58-DC92-4211-B603-6344D893D946

Q37082518-D8364528-5F28-4940-9201-26F522BBF27C

P2860

Q37082518-006E5826-3A86-4CEC-91A0-E604D22D42EA

Q37082518-0FD99CB5-90AD-4CA8-9DB7-0A3C4A7BCFFC

Q37082518-129C3F51-18F1-44C2-AD98-1EC9B23A469E

Q37082518-155B6D5F-114F-4726-9F7F-0CDB5D904BDC

Q37082518-35D6A2A5-51A6-48C2-9F1E-A7E1FF4D6832

Q37082518-4FD5E46A-4ADA-4D94-BABF-19739540A9E3

Q37082518-52D3A96E-9F95-4AB8-A180-FDD132806181

Q37082518-543DEA9A-3A69-45AC-B103-C4FDB7F84FC0

Q37082518-5497C63F-97F7-46D8-BEB0-732738C06D2C

Q37082518-54DD74E3-3748-4247-994E-77EF524C3626

P304

Q37082518-E9232A33-97B7-48E1-BA2E-3F5E6EAF27C1

P31

Q37082518-EB76E40D-3D9A-4E95-87A9-341619BC3A8A

P356

Q37082518-84E996BC-8D66-40B6-BD21-3D5EF30FE22D

P433

Q37082518-F6232226-7322-4937-8784-14655EE3402E

P478

Q37082518-9B8798D4-D1C3-479F-B093-FEE990B302D7

P50

Q37082518-82CD39EC-90BB-445E-9EE7-F643D4879E59

P577

Q37082518-FD03F062-8BC1-4A0E-80D8-AE0B5A775EEC

P698

Q37082518-99257E57-AF2D-492D-8AA6-66AACC0FCE73

P932

Q37082518-AB64C65C-5E22-4A2F-9091-ADFE3816C661

P356

P1433

The journal of pathology. Clinical research

P1476

Cancer-testis antigens PRAME a ...... rognosis in myxoid liposarcoma

@en

P2093

Akira Maekawa

http://www.w3.org/2001/XMLSchema#string

Hidetaka Yamamoto

http://www.w3.org/2001/XMLSchema#string

Kenichi Kohashi

http://www.w3.org/2001/XMLSchema#string

Kunio Iura

http://www.w3.org/2001/XMLSchema#string

Yoshinao Oda

http://www.w3.org/2001/XMLSchema#string

Yuichi Yamada

http://www.w3.org/2001/XMLSchema#string

Yuka Hotokebuchi

http://www.w3.org/2001/XMLSchema#string

Yukihide Iwamoto

http://www.w3.org/2001/XMLSchema#string

P2860

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling

Quantitative monitoring of gene expression patterns with a complementary DNA microarray

Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)

Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer

Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.

Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors

P304

144-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CJP2.16

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27499900

http://www.w3.org/2001/XMLSchema#string

P932

4939879

http://www.w3.org/2001/XMLSchema#string